Antibody maintenance 3 months after complete messenger RNA COVID-19 vaccination in haemodialysis patients
Open Access
- 17 September 2021
- journal article
- letter
- Published by Oxford University Press (OUP) in Nephrology Dialysis Transplantation
- Vol. 36 (12) , 2340-2341
Abstract
In-centre haemodialysis (HD) patients have a greater risk of sudden acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and more significant mortality associated with coronavirus disease 2019 (COVID-19) than the general population [ 1, 2], which made their vaccination a priority for healthcare authorities [ 3]. Even though real-world data on vaccine efficacy in preventing severe COVID-19 in the HD subpopulation are lacking, and antibody levels have only been indirectly associated with viral neutralization [ 4], several published studies have evaluated the humoral response of these patients after completing vaccination with mRNA-1273 (Moderna) and BNT162b2 (Pfizer-BioNTech) vaccines in terms of seroconversion and intensity (i.e. antibody levels) as an efficacy surrogate, with satisfactory results. The results were similar to those observed in the general population except for patients receiving immunosuppressive medication during vaccination [ 5–7]. Recently there has been evidence of persistent, although declining [ 8], antibody positivity in healthy vaccinated individuals with both mRNA-1273 and BNT162b2 vaccines 3 and 6 months after completing vaccination [ 9–12]. Given the known impaired cellular and humoral responses of HD patients to other immunization programs (e.g. hepatitis B, influenza) [ 13, 14], there was concern regarding the durability of the SARS-CoV-2 vaccine’s effect in this population. Therefore we aimed to determine anti-spike S1 receptor-binding domain (anti-S1-RBD) immunoglobulin G (IgG) presence and degree of decline 3 months after completing vaccination.Keywords
This publication has 14 references indexed in Scilit:
- Humoral and Cellular Responses to mRNA-1273 and BNT162b2 SARS-CoV-2 Vaccines Administered to Hemodialysis PatientsAmerican Journal of Kidney Diseases, 2021
- Antibody Response to mRNA-1273 SARS-CoV-2 Vaccine in Hemodialysis Patients with and without Prior COVID-19Clinical Journal of the American Society of Nephrology, 2021
- Humoral Response to the Pfizer BNT162b2 Vaccine in Patients Undergoing Maintenance HemodialysisClinical Journal of the American Society of Nephrology, 2021
- Antibody Persistence through 6 Months after the Second Dose of mRNA-1273 Vaccine for Covid-19New England Journal of Medicine, 2021
- Clinical validation of the Siemens quantitative SARS-CoV-2 spike IgG assay (sCOVG) reveals improved sensitivity and a good correlation with virus neutralization titersClinical Chemistry and Laboratory Medicine (CCLM), 2021
- Durability of Responses after SARS-CoV-2 mRNA-1273 VaccinationNew England Journal of Medicine, 2021
- SARS-CoV-2 Infection in a Spanish Cohort of CKD-5D Patients: Prevalence, Clinical Presentation, Outcomes, and De-Isolation ResultsBlood Purification, 2020
- Prevalence of COVID-19 Infection in Hemodialysis Patients Detected Using Serologic ScreeningJournal of the American Society of Nephrology, 2020
- Factors affecting effectiveness of vaccination against hepatitis B virus in hemodialysis patientsWorld Journal of Gastroenterology, 2014
- Influenza A/H1N1 Vaccine in Patients Treated by Kidney Transplant or DialysisClinical Journal of the American Society of Nephrology, 2011